Atsena is a clinical stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company’s lead gene therapy program is in an ongoing Phase I/II trial for patients with GUCY2D-associated Leber congenital amaurosis (LCA1), one of the most common causes of blindness in children. The company also has a robust pipeline of preclinical gene therapy programs leveraging novel tools and capsids aimed to treat patients with other inherited retinal diseases.